In PTEN-deficient prostate cancer models, downregulation of AKT2, but not AKT1, promoted regression of prostate cancer xenografts through upregulation of p21 and the pro-apoptotic protein Bax, and downregulation of insulin-like growth factor receptor-1 [55]. This evidence concerns the gene BAX and prostate carcinoma.